Stephen Hasak
Stephen Hasak has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Raya Alashram
Department of Internal Medicine
2 shared publications - Seth Richter
Division of Gastroenterology & Hepatology
2 shared publications - Ahmad Abulawi
Department of Medicine, Albany Medical Center, Albany, NY
1 shared publication - Ahmad Abulawi
Division of Gastroenterology & Hepatology, Albany Medical College, Albany, USA
1 shared publication - Aqsa Khan
Parkview Health, Fort Wayne, USA
1 shared publication - Asra Batool
Division of Gastroenterology & Hepatology
1 shared publication
Latest Publications
- 30 October 2025
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
Real-World Evidence
Background and aims: Colorectal cancer is the second leading cause of cancer death in the United States, yet ∼25% of patients undergoing colonoscopy have suboptimal bowel preparation. Bowel preparation is cited as the leading deterrent to an elective colonoscopy. Methods: This randomized, controlled, single-blinded noninferiority trial assessed the efficacy, safety, and patient tolerability of oral sulfate tablets (OST) compared with polyethylene glycol (PEG) based bowel preparation formulations, with explicit consideration of patient satisfaction and adverse events. Between March and August 2024, adult outpatients at Albany Medical Center requiring routine colonoscopies were consented and enrolled. Endoscopists were blinded to preparation assignments and graded the cleansing of the colon based on the US FDA Bowel Prep Scoring Scale. Patients completed a preparation satisfaction questionnaire. Results: This study assessed 177 patients (n=94 OST/n=83 PEG). Overall cleansing scores favored OST with 67.0% “excellent” preparations versus 57.8% for PEG. Although differences were not statistically significant in segmental analyses, trends favored OST. Generally, bowel preparation cleansing scores for the proximal, mid, and distal colon were numerically better for OST. Polyp identification was higher for OST (60.6%) versus PEG (54.2%). Tolerability favored OST, with 18.1% of patients in the OST group reporting adverse events (AE) versus 65.1% of patients in the PEG group. The most common AE for both groups was nausea. OST was “tolerable” to “very easy” to consume in 88.3% of patients compared with 78.6% for patients in the PEG group. OST was again requested by 92.6% of patients, compared with 60.7% of patients in the PEG group. Conclusions: This real-world study demonstrates the noninferior efficacy and safety of OST compared with conventional PEG-based formulations while highlighting improved patient tolerability, palatability, and potential preference bias due to free-of-charge provision.
- 30 October 2025
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
Real-World Evidence
Background and aims: Colorectal cancer is the second leading cause of cancer death in the United States, yet ∼25% of patients undergoing colonoscopy have suboptimal bowel preparation. Bowel preparation is cited as the leading deterrent to an elective colonoscopy. Methods: This randomized, controlled, single-blinded noninferiority trial assessed the efficacy, safety, and patient tolerability of oral sulfate tablets (OST) compared with polyethylene glycol (PEG) based bowel preparation formulations, with explicit consideration of patient satisfaction and adverse events. Between March and August 2024, adult outpatients at Albany Medical Center requiring routine colonoscopies were consented and enrolled. Endoscopists were blinded to preparation assignments and graded the cleansing of the colon based on the US FDA Bowel Prep Scoring Scale. Patients completed a preparation satisfaction questionnaire. Results: This study assessed 177 patients (n=94 OST/n=83 PEG). Overall cleansing scores favored OST with 67.0% “excellent” preparations versus 57.8% for PEG. Although differences were not statistically significant in segmental analyses, trends favored OST. Generally, bowel preparation cleansing scores for the proximal, mid, and distal colon were numerically better for OST. Polyp identification was higher for OST (60.6%) versus PEG (54.2%). Tolerability favored OST, with 18.1% of patients in the OST group reporting adverse events (AE) versus 65.1% of patients in the PEG group. The most common AE for both groups was nausea. OST was “tolerable” to “very easy” to consume in 88.3% of patients compared with 78.6% for patients in the PEG group. OST was again requested by 92.6% of patients, compared with 60.7% of patients in the PEG group. Conclusions: This real-world study demonstrates the noninferior efficacy and safety of OST compared with conventional PEG-based formulations while highlighting improved patient tolerability, palatability, and potential preference bias due to free-of-charge provision.
- 8 February 2025
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 27 (1) , 1-8
Gastrointestinal Subepithelial Lesions: Evolution in Management and Endoscopic Resection Techniques
Purpose of Review Subepithelial lesions (SELs) are tumors originating from the gastrointestinal (GI) tract wall (muscularis mucosa, submucosa, or muscularis propria) and are covered by overlying mucosa. They are typically incidental findings during routine endoscopy. This article reviews the latest advancements in endoscopic techniques and devices used to resect subepithelial lesions. Recent Findings Endoscopic Ultrasound (EUS) should be employed to characterize SELs, with fine needle core biopsy (FNB) utilized with EUS for histopathologic tissue acquisition. EUS can be used as “endoscopic mapping” to mitigate serious complications prior to endoscopic resection. Techniques such as Submucosal Tunnelling Endoscopic Resection (STER), Device-Assisted Endoscopic Full Thickness Resection, and Freehand Full Thickness Resection are available for the complete resection of SELs. The choice of technique depends on the characteristics of the lesion and the level of expertise of the endoscopist. Summary Multiple endoscopic resection techniques for SELs have been developed, each utilizing different tools and devices. A significant shift has occurred from traditional laparoscopic surgical resection to minimally invasive, organ-sparing endoscopic resection. Advancements in “third space” endoscopy and the innovation of novel devices continue to offer less invasive resection techniques for lesions arising from the GI tract wall.
- 8 February 2025
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 27 (1) , 1-8
Gastrointestinal Subepithelial Lesions: Evolution in Management and Endoscopic Resection Techniques
Purpose of Review Subepithelial lesions (SELs) are tumors originating from the gastrointestinal (GI) tract wall (muscularis mucosa, submucosa, or muscularis propria) and are covered by overlying mucosa. They are typically incidental findings during routine endoscopy. This article reviews the latest advancements in endoscopic techniques and devices used to resect subepithelial lesions. Recent Findings Endoscopic Ultrasound (EUS) should be employed to characterize SELs, with fine needle core biopsy (FNB) utilized with EUS for histopathologic tissue acquisition. EUS can be used as “endoscopic mapping” to mitigate serious complications prior to endoscopic resection. Techniques such as Submucosal Tunnelling Endoscopic Resection (STER), Device-Assisted Endoscopic Full Thickness Resection, and Freehand Full Thickness Resection are available for the complete resection of SELs. The choice of technique depends on the characteristics of the lesion and the level of expertise of the endoscopist. Summary Multiple endoscopic resection techniques for SELs have been developed, each utilizing different tools and devices. A significant shift has occurred from traditional laparoscopic surgical resection to minimally invasive, organ-sparing endoscopic resection. Advancements in “third space” endoscopy and the innovation of novel devices continue to offer less invasive resection techniques for lesions arising from the GI tract wall.
- 1 January 2025
- Published by Springer Nature
- p. 183-200
Autoimmune Cholangiopathies
- Open Access
Gastric Cancer Due to Chronic H. pylori Infection: What We Know and Where We Are Going
Helicobacter pylori is an established cause of many gastrointestinal pathologies including peptic ulcer disease, gastritis, and gastric cancer. It is an entity that affects the global population, and its true nature has only been known since the 1980s. Although there is much known about H. pylori including its pathophysiology, detection, and eradication, resistance to current therapy models is common. This is problematic because untreated or inadequately treated H. pylori increases morbidity and mortality related to gastric cancer and peptic ulcer disease among others. In order to improve the treatment and reduce resistance, there is significant ongoing research identifying new detection and eradication methods for H. pylori. This review aims to highlight what has already been established regarding H. pylori’s epidemiology, pathophysiology, detection, and treatment as well as the most current and novel research involving detection and treatment of H. pylori.
Open AccessGastric Cancer Due to Chronic H. pylori Infection: What We Know and Where We Are Going
Helicobacter pylori is an established cause of many gastrointestinal pathologies including peptic ulcer disease, gastritis, and gastric cancer. It is an entity that affects the global population, and its true nature has only been known since the 1980s. Although there is much known about H. pylori including its pathophysiology, detection, and eradication, resistance to current therapy models is common. This is problematic because untreated or inadequately treated H. pylori increases morbidity and mortality related to gastric cancer and peptic ulcer disease among others. In order to improve the treatment and reduce resistance, there is significant ongoing research identifying new detection and eradication methods for H. pylori. This review aims to highlight what has already been established regarding H. pylori’s epidemiology, pathophysiology, detection, and treatment as well as the most current and novel research involving detection and treatment of H. pylori.